RBC Capital downgraded EyePoint Pharmaceuticals (NASDAQ:EYPT) due to mixed Phase 3 trial results for its wet AMD drug, DURAVYU. The LUGANO trial for DURAVYU missed its primary endpoint, influenced by a small patient subgroup, despite showing comparable efficacy to standard treatment and a 42% reduction in treatment burden in a separate analysis. EyePoint's stock plummeted over 66.98% to a 52-week low of $3.95, further pressured by positive trial data from competitor REGENXBIO (NASDAQ:RGNX) for its own wet ...